(Q38218923)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24913374%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

title

Metronomics: towards personalized chemotherapy? (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24913374%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

1 reference

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24913374%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

author name string

Nicolas André

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24913374%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

Manon Carré

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24913374%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

language of work or name

English

0 references

publication date

10 June 2014

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24913374%20AND%20SRC:MED&resulttype=core&format=json

Nature Reviews Clinical Oncology

20 March 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24913374%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

volume

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24913374%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

issue

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24913374%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

page(s)

413-431

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24913374%20AND%20SRC:MED&resulttype=core&format=json

Tumor angiogenesis: therapeutic implications

20 March 2020

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.89

Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.89

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.89

The anti-angiogenic basis of metronomic chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.89

Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.89

Repopulation of cancer cells during therapy: an important cause of treatment failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.89

Therapy-induced acute recruitment of circulating endothelial progenitor cells to tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.89

Optimal biologic dose of metronomic chemotherapy regimens is associated with maximum antiangiogenic activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.89

A change of strategy in the war on cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.89

For cancer, seek and destroy or live and let live?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.89

Metronomic chemotherapy: new rationale for new directions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.89

Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.89

Nontoxic, fiscally responsible, future of oncology: could it be beginning in the Third World?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.89

A randomized phase III trial of IV carboplatin and paclitaxel × 3 courses followed by observation versus weekly maintenance low-dose paclitaxel in patients with early-stage ovarian carcinoma: a Gynecologic Oncology Group Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.89

Metronomic scheduling of anticancer treatment: the next generation of multitarget therapy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.89

The prince and the pauper. A tale of anticancer targeted agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.89

Drug repositioning: identifying and developing new uses for existing drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.89

Drug repurposing in pediatrics and pediatric hematology oncology

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.89

Has the time come for metronomics in low-income and middle-income countries?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.89

Metronomic chemotherapy: an antiangiogenic scheduling

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.89

Concentration- and schedule-dependent effects of chemotherapy on the angiogenic potential and drug sensitivity of vascular endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.89

Circulating endothelial-cell kinetics and viability predict survival in breast cancer patients receiving metronomic chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.89

The anticancer immune response: indispensable for therapeutic success?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.89

The secret ally: immunostimulation by anticancer drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.89

Immunogenic cancer cell death: a key-lock paradigm

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.89

Chemomodulation of human dendritic cell function by antineoplastic agents in low noncytotoxic concentrations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.89

Chemotherapeutic agents in low noncytotoxic concentrations increase immunogenicity of human colon cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.89

Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.89

Treg depletion with a low-dose metronomic temozolomide regimen in a rat glioma model

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.89

Selective depletion of CD4+CD25+Foxp3+ regulatory T cells by low-dose cyclophosphamide is explained by reduced intracellular ATP levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.89

Paclitaxel promotes differentiation of myeloid-derived suppressor cells into dendritic cells in vitro in a TLR4-independent manner

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.89

Combination of lentivector immunization and low-dose chemotherapy or PD-1/PD-L1 blocking primes self-reactive T cells and induces anti-tumor immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.89

The combination of a low-dose chemotherapeutic agent, 5-fluorouracil, and an adenoviral tumor vaccine has a synergistic benefit on survival in a tumor model system.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.89

Combining conventional chemotherapy and γδ T cell-based immunotherapy to target cancer-initiating cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.89

Metronomic chemotherapy enhances antitumor effects of cancer vaccine by depleting regulatory T lymphocytes and inhibiting tumor angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.89

Immunotherapy with HER-2 and VEGF peptide mimics plus metronomic paclitaxel causes superior antineoplastic effects in transplantable and transgenic mouse models of human breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.89

Intermittent metronomic drug schedule is essential for activating antitumor innate immunity and tumor xenograft regression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.89

Single low-dose cyclophosphamide combined with interleukin-12 gene therapy is superior to a metronomic schedule in inducing immunity against colorectal carcinoma in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.89

Anticancer therapies combining antiangiogenic and tumor cell cytotoxic effects reduce the tumor stem-like cell fraction in glioma xenograft tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.89

Metronomic chemotherapy following the maximum tolerated dose is an effective anti-tumour therapy affecting angiogenesis, tumour dissemination and cancer stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.89

Drug-tolerant cancer cells show reduced tumor-initiating capacity: depletion of CD44 cells and evidence for epigenetic mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.89

Cooperativity of CD44 and CD49d in leukemia cell homing, migration, and survival offers a means for therapeutic attack

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.89

Increased tumor oxygenation and drug uptake during anti-angiogenic weekly low dose cyclophosphamide enhances the anti-tumor effect of weekly tirapazamine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.89

Metronomic gemcitabine suppresses tumour growth, improves perfusion, and reduces hypoxia in human pancreatic ductal adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.89

Low-dose metronomic oral dosing of a prodrug of gemcitabine (LY2334737) causes antitumor effects in the absence of inhibition of systemic vasculogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.89

Multihistology, target-driven pilot trial of oral topotecan as an inhibitor of hypoxia-inducible factor-1α in advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.89

Anthracycline chemotherapy inhibits HIF-1 transcriptional activity and tumor-induced mobilization of circulating angiogenic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.89

Overcoming evasive resistance from vascular endothelial growth factor a inhibition in sarcomas by genetic or pharmacologic targeting of hypoxia-inducible factor 1α.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.89

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.89

A multitargeted, metronomic, and maximum-tolerated dose "chemo-switch" regimen is antiangiogenic, producing objective responses and survival benefit in a mouse model of cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.89

Control dominating subclones for managing cancer progression and posttreatment recurrence by subclonal switchboard signal: implication for new therapies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.89

Metronomic gemcitabine in combination with sunitinib inhibits multisite metastasis and increases survival in an orthotopic model of pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.89

Potent preclinical impact of metronomic low-dose oral topotecan combined with the antiangiogenic drug pazopanib for the treatment of ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.89

Suppression of hepatic tumor growth and metastasis by metronomic therapy in a rat model of hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.89

Metronomic oral topotecan with pazopanib is an active antiangiogenic regimen in mouse models of aggressive pediatric solid tumor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.89

Ischaemia-induced mucus barrier loss and bacterial penetration are rapidly counteracted by increased goblet cell secretory activity in human and rat colon

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.89

Preclinical recapitulation of antiangiogenic drug clinical efficacies using models of early or late stage breast cancer metastatis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.89

Instructive role of the vascular niche in promoting tumour growth and tissue repair by angiocrine factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.89

Interaction between regulatory T cells and cancer stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.89

Knockout of HIF-1α in tumor-associated macrophages enhances M2 polarization and attenuates their pro-angiogenic responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.89

Tumors that acquire resistance to low-dose metronomic cyclophosphamide retain sensitivity to maximum tolerated dose cyclophosphamide

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.89

Chemoresistance to temozolomide in human glioma cell line U251 is associated with increased activity of O6-methylguanine-DNA methyltransferase and can be overcome by metronomic temozolomide regimen

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.89

Preclinical analysis of resistance and cross-resistance to low-dose metronomic chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.89

Chemotherapy dosing schedule influences drug resistance development in ovarian cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.89

Residual dormant cancer stem-cell foci are responsible for tumor relapse after antiangiogenic metronomic therapy in hepatocellular carcinoma xenografts

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.89

Low-dose metronomic daily cyclophosphamide and weekly tirapazamine: a well-tolerated combination regimen with enhanced efficacy that exploits tumor hypoxia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.89

In vivo chemoresistance of prostate cancer in metronomic cyclophosphamide therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.89

A Comprehensive Gene Expression Analysis of Resistance Formation upon Metronomic Cyclophosphamide Therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.89

Differential expression of mimecan and thioredoxin domain-containing protein 5 in colorectal adenoma and cancer: a proteomic study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.89

The influence of TXNDC5 gene on gastric cancer cell

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.89

Chemotherapy-triggered cathepsin B release in myeloid-derived suppressor cells activates the Nlrp3 inflammasome and promotes tumor growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.89

Dose selection trial of metronomic oral vinorelbine monotherapy in patients with metastatic cancer: a hellenic cooperative oncology group clinical translational study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.89

Phase I trial of metronomic oral vinorelbine in patients with advanced cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.89

Capecitabine "metronomic" chemotherapy for palliative treatment of elderly patients with advanced gastric cancer after fluoropyrimidine-based chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.89

Metronomic oral combination chemotherapy with capecitabine and cyclophosphamide: a phase II study in patients with HER2-negative metastatic breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.89

Phase II trial of continuous low-dose temozolomide for patients with recurrent malignant glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.89

Metronomic chemotherapy in metastatic breast cancer: impact on VEGF.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.89

Salvage therapy with oral metronomic cyclophosphamide and methotrexate for castration-refractory metastatic adenocarcinoma of the prostate resistant to docetaxel

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.89

Multicenter Phase II Study of a New Effective S-1 and Irinotecan Combination Schedule in Patients with Unresectable Metastatic or Recurrent Colorectal Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.89

Targeting microtubules to inhibit angiogenesis and disrupt tumour vasculature: implications for cancer treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.89

Efficacy and tolerability of vinorelbine in the cancer therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.89

Optimising the dose of capecitabine in metastatic breast cancer: confused, clarified or confirmed?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.89

Safety and pharmacokinetics of temozolomide using a dose-escalation, metronomic schedule in recurrent paediatric brain tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.89

Anti-angiogenic treatment of breast cancer using metronomic low-dose chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.89

Comparative impact of trastuzumab and cyclophosphamide on HER-2-positive human breast cancer xenografts

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.89

A randomized trial of adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.89

Oral uracil and tegafur compared with classic cyclophosphamide, methotrexate, fluorouracil as postoperative chemotherapy in patients with node-negative, high-risk breast cancer: National Surgical Adjuvant Study for Breast Cancer 01 Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.89

Protracted low dose of oral vinorelbine and temozolomide with whole-brain radiotherapy in the treatment for breast cancer patients with brain metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.89

CNS metastases in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.89

Prospective study of carmustine wafers in combination with 6-month metronomic temozolomide and radiation therapy in newly diagnosed glioblastoma: preliminary results.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.89

Adjuvant pegylated liposomal doxorubicin for older women with endocrine nonresponsive breast cancer who are NOT suitable for a "standard chemotherapy regimen": the CASA randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.89

Pegylated liposomal doxorubicin in combination with low-dose metronomic cyclophosphamide as preoperative treatment for patients with locally advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.89

Activity of a multitargeted chemo-switch regimen (sorafenib, gemcitabine, and metronomic capecitabine) in metastatic renal-cell carcinoma: a phase 2 study (SOGUG-02-06).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.89

Neurocognitive function after radiotherapy for paediatric brain tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.89

Phase II study of metronomic chemotherapy with bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.89

Phase II study of weekly paclitaxel and sorafenib as second/third-line therapy in patients with adrenocortical carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.89

The combination of intravenous bevacizumab and metronomic oral cyclophosphamide is an effective regimen for platinum-resistant recurrent ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.89

Bevacizumab plus low-dose metronomic oral cyclophosphamide in heavily pretreated patients with recurrent ovarian cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.89

Combination antiangiogenic therapy in advanced breast cancer: a phase 1 trial of vandetanib, a VEGFR inhibitor, and metronomic chemotherapy, with correlative platelet proteomics

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.89

Metronomic chemotherapy combined with bevacizumab and erlotinib in patients with metastatic HER2-negative breast cancer: clinical and biological activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.89

A phase 1 trial of imatinib, bevacizumab, and metronomic cyclophosphamide in advanced colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.89

Phase II trial of bevacizumab and dose/dense chemotherapy with cisplatin and metronomic daily oral etoposide in advanced non-small-cell-lung cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.89

A phase II randomized trial of gefitinib alone or with tegafur/uracil treatment in patients with pulmonary adenocarcinoma who had failed previous chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.89

Phase II study of combining sorafenib with metronomic tegafur/uracil for advanced hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.89

A phase I study of veliparib in combination with metronomic cyclophosphamide in adults with refractory solid tumors and lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.89

Combination treatment with metronomic temozolomide, bevacizumab and long-acting octreotide for malignant neuroendocrine tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.89

A phase II trial of erlotinib in combination with bevacizumab in patients with metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.89

Corticosteroid-sparing agents: conventional systemic immunosuppressants

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.89

Molecular determinants of immunogenic cell death elicited by anticancer chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.89

Oncolytic adenovirus with temozolomide induces autophagy and antitumor immune responses in cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.89

Immunological effects of low-dose cyclophosphamide in cancer patients treated with oncolytic adenovirus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.89

Autologous lysate-pulsed dendritic cell vaccination followed by adoptive transfer of vaccine-primed ex vivo co-stimulated T cells in recurrent ovarian cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.89

Addition of an induction regimen of antiangiogenesis and antitumor immunity to standard chemotherapy improves survival in advanced malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.89

Metronomic Cyclophosphamide and Methotrexate Chemotherapy Combined with 1E10 Anti-Idiotype Vaccine in Metastatic Breast Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.89

Pioglitazone, etoricoxib, interferon-α, and metronomic capecitabine for metastatic renal cell carcinoma: final results of a prospective phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.89

Continuous low-dose cyclophosphamide and methotrexate combined with celecoxib for patients with advanced cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.89

Safety and therapeutic effect of metronomic chemotherapy with cyclophosphamide and celecoxib in advanced breast cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.89

Metronomic chemotherapy with cyclophosphamide and dexamethasone in patients with metastatic carcinoma of the prostate

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.89

Evaluation of oral chemotherapy with capecitabine and cyclophosphamide plus thalidomide and prednisone in prostate cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.89

Oral metronomic cyclophosphamide and methotrexate plus fulvestrant in advanced breast cancer patients: a mono-institutional case-cohort report.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.89

Phase ii trial of a metronomic schedule of docetaxel and capecitabine with concurrent celecoxib in patients with prior anthracycline exposure for metastatic breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.89

Oral metronomic chemotherapy in recurrent, metastatic and locally advanced head and neck cancers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.89

Clinical, pharmacokinetic and pharmacodynamic evaluations of metronomic UFT and cyclophosphamide plus celecoxib in patients with advanced refractory gastrointestinal cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.89

Feasibility of metronomic oral cyclophosphamide plus prednisolone in elderly patients with inoperable or metastatic soft tissue sarcoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.89

Metronomic therapy is an effective salvage treatment for heavily pre-treated relapsed/refractory multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.89

A phase 2 pilot trial of low-dose, continuous infusion, or "metronomic" paclitaxel and oral celecoxib in patients with metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.89

A multi-centre Canadian pilot study of metronomic temozolomide combined with radiotherapy for newly diagnosed paediatric brainstem glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.89

Children treated with metronomic chemotherapy in a low-income country: METRO-MALI-01.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.89

A phase I study of zoledronic acid and low-dose cyclophosphamide in recurrent/refractory neuroblastoma: a new approaches to neuroblastoma therapy (NANT) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.89

Metronomic chemotherapy with the COMBAT regimen in advanced pediatric malignancies: a multicenter experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.89

Preliminary evaluation of children treated with metronomic chemotherapy and valproic acid in a low-income country: Metro-Mali-02.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.89

A phase II study of metronomic oral topotecan for recurrent childhood brain tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.89

A pilot study of low-dose anti-angiogenic chemotherapy in combination with standard multiagent chemotherapy for patients with newly diagnosed metastatic Ewing sarcoma family of tumors: A Children's Oncology Group (COG) Phase II study NCT00061893.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.89

Pilot study of a pediatric metronomic 4-drug regimen

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.89

Antiangiogenic combination therapy after local radiotherapy with topotecan radiosensitizer improved quality of life for children with inoperable brainstem gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.89

Antiangiogenic metronomic therapy for children with recurrent embryonal brain tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.89

A feasibility trial of antiangiogenic (metronomic) chemotherapy in pediatric patients with recurrent or progressive cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.89

Treating childhood acute lymphoblastic leukemia without cranial irradiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.89

Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.89

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.89

Capecitabine Versus Classical Cyclophosphamide, Methotrexate, and Fluorouracil As First-Line Chemotherapy for Advanced Breast Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.89

Efficacy and safety of metronomic chemotherapy for patients with advanced primary hepatocellular carcinoma with major portal vein tumor thrombosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.89

The evolution of melanoma resistance reveals therapeutic opportunities

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.89

Single-drug vinblastine as salvage treatment for refractory or relapsed anaplastic large-cell lymphoma: a report from the French Society of Pediatric Oncology

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.89

Vinblastine in children and adolescents with high-risk anaplastic large-cell lymphoma: results of the randomized ALCL99-vinblastine trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.89

Phase II study of 21 day schedule oral etoposide in children. New Agents Group of the United Kingdom Children's Cancer Study Group (UKCCSG).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.89

Vinorelbine in previously treated advanced childhood sarcomas: evidence of activity in rhabdomyosarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.89

Phase II study of metronomic chemotherapy for recurrent malignant gliomas in adults.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.89

UKT-04 trial of continuous metronomic low-dose chemotherapy with methotrexate and cyclophosphamide for recurrent glioblastoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.89

Thrombospondin 1, a mediator of the antiangiogenic effects of low-dose metronomic chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.89

A pilot pharmacokinetic and antiangiogenic biomarker study of celecoxib and low-dose metronomic vinblastine or cyclophosphamide in pediatric recurrent solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.89

Increased mean corpuscular volume of red blood cells predicts response to metronomic capecitabine and cyclophosphamide in combination with bevacizumab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.89

Itraconazole and arsenic trioxide inhibit Hedgehog pathway activation and tumor growth associated with acquired resistance to smoothened antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.89

Propranolol potentiates the anti-angiogenic effects and anti-tumor efficacy of chemotherapy agents: implication in breast cancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.89

β-blockers increase response to chemotherapy via direct antitumour and anti-angiogenic mechanisms in neuroblastoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.89

A drug repositioning approach identifies tricyclic antidepressants as inhibitors of small cell lung cancer and other neuroendocrine tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.89

Pharmacogenetics and pharmacogenomics: a bridge to individualized cancer therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.89

Clinical pharmacogenetics implementation consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing: 2013 update

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.89

A mathematical model for the administration of temozolomide: comparative analysis of conventional and metronomic chemotherapy regimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.89

Maximum tolerated dose versus metronomic scheduling in the treatment of metastatic cancers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.89

Network-enabled gene expression analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.89

Using pharmacokinetic and pharmacodynamic modeling and simulation to evaluate importance of schedule in topotecan therapy for pediatric neuroblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.89

Generalized principles of stochasticity can be used to control dynamic heterogeneity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.89

Center of cancer systems biology second annual workshop--tumor metronomics: timing and dose level dynamics

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.89

Formalizing an integrative, multidisciplinary cancer therapy discovery workflow

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.89

The person in personalised medicine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.89

An all-oral combination of metronomic cyclophosphamide plus capecitabine in patients with anthracycline- and taxane-pretreated metastatic breast cancer: a phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.89

Randomized Phase II Trial of Letrozole and Letrozole Plus Low-Dose Metronomic Oral Cyclophosphamide As Primary Systemic Treatment in Elderly Breast Cancer Patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.89

Looking at the Seemingly Contradictory Role of Vinblastine in Anaplastic Large-Cell Lymphoma From a Metronomic Perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.89

Transplacental carcinogenesis by stilbestrol

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.89

Redefining the target: chemotherapeutics as antiangiogenics

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.89

Chemotherapeutic drugs--more really is not better

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.89

Continuous low-dose anti-angiogenic/ metronomic chemotherapy: from the research laboratory into the oncology clinic

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.89

Oral metronomic scheduling of anticancer therapy-based treatment compared to existing standard of care in locally advanced oral squamous cell cancers: A matched-pair analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.89

Low-dose oral methotrexate and cyclophosphamide in metastatic breast cancer: antitumor activity and correlation with vascular endothelial growth factor levels

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.89

Metronomic oral topotecan prolongs survival and reduces liver metastasis in improved preclinical orthotopic and adjuvant therapy colon cancer models

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.89

Response of recurrent medulloblastoma to low-dose oral etoposide

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.89

Investigating a pathogenic role for TXNDC5 in tumors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.89

A phase II study of metronomic oral vinorelbine administered in the second line and beyond in non-small cell lung cancer (NSCLC): a phase II study of the Hellenic Oncology Research Group

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.89

A phase I trial of oral metronomic vinorelbine plus capecitabine in patients with metastatic breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.89

Efficacy and safety of low-dose metronomic chemotherapy with capecitabine in heavily pretreated patients with metastatic breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.89

Protracted low doses of temozolomide for the treatment of patients with recurrent glioblastoma: A phase II study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.89

Metronomic oral cyclophosphamide in patients with advanced solid tumors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.89

Phase II clinical trial of metronomic chemotherapy with combined irinotecan and tegafur-gimeracil-oteracil potassium in metastatic and recurrent breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.89

Oral etoposide for refractory and relapsed neuroblastoma.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.89

A multicenter phase I trial of metronomic oral vinorelbine plus cisplatin in patients with NSCLC

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.89

Cancer immunologists and cancer biologists: why we didn't talk then but need to now

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.89

Metastatic melanoma patients treated with dendritic cell vaccination, Interleukin-2 and metronomic cyclophosphamide: results from a phase II trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.89

Effective oral combination metronomic chemotherapy with low toxicity for the management of castration-resistant prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.89

Metronomic therapy for refractory/relapsed lymphoma: the PEP-C low-dose oral combination chemotherapy regimen.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.89

Metronomic therapy with cyclophosphamide and dexamethasone for prostate carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.89

Phase II study of vinorelbine and continuous low doses cyclophosphamide in children and young adults with a relapsed or refractory malignant solid tumour: good tolerance profile and efficacy in rhabdomyosarcoma--a report from the Société Française d

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.89

Embryonal rhabdomyosarcoma with metastases confined to the lungs: report from the CWS Study Group

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.89

High-time chemotherapy or high time for low dose

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.89

Circulating thrombospondin 1 level as a surrogate marker in patients receiving cyclophosphamide-based metronomic chemotherapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.89

Integrating pharmacogenetics into gemcitabine dosing--time for a change?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.89

Fine-tuning anti-tumor immunotherapies via stochastic simulations.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.89

Combination metronomic oral topotecan and pazopanib: a pharmacokinetic study in patients with gynecological cancer.

31 March 2020

1 reference

12 December 2020

Metronomic oral cyclophosphamide prednisolone chemotherapy is an effective treatment for metastatic hormone-refractory prostate cancer after docetaxel failure.

1 reference

12 December 2020

Expression of angiogenic markers in the peripheral blood of docetaxel-treated advanced breast cancer patients: a Hellenic Cooperative Oncology Group (HeCOG) study.

1 reference

12 December 2020

Sorafenib plus daily low-dose temozolomide for relapsed glioblastoma: a phase II study.

1 reference

12 December 2020

Identification of small molecule inhibitors of hypoxia-inducible factor 1 transcriptional activation pathway.

1 reference

12 December 2020

Low-dose metronomic oral administration of vinorelbine in the first-line treatment of elderly patients with metastatic breast cancer.

1 reference

12 December 2020

Immunological Mechanisms of Low and Ultra-Low Dose Cancer Chemotherapy

1 reference

12 December 2020

Metronomic vinorelbine plus bevacizumab as salvage therapy for patients with metastatic breast cancer.

1 reference

12 December 2020

Repeated tumor oximetry to identify therapeutic window during metronomic cyclophosphamide treatment of 9L gliomas

1 reference

12 December 2020

Suppressive effects of cyclophosphamide and gemcitabine on regulatory T-cell induction in vitro

1 reference

12 December 2020

Oral metronomic cyclophosphamide with and without methotrexate as palliative treatment for patients with metastatic breast carcinoma

1 reference

12 December 2020

Maximum tolerable dose and low-dose metronomic chemotherapy have opposite effects on the mobilization and viability of circulating endothelial progenitor cells.

1 reference

12 December 2020

Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer

1 reference

12 December 2020

Synergistic effect of metronomic dosing of cyclophosphamide combined with specific antitumor immunotherapy in a murine melanoma model.

1 reference

12 December 2020

Overexpression of the TXNDC5 protein in non-small cell lung carcinoma.

1 reference

12 December 2020

10.1038/NRCLINONC.2014.89

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24913374%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

1 reference